Mikołaj Slabicki, PhD

Mikolaj.png

Mikołaj Słabicki is a Group Leader in the Cancer Program at the Broad Institute, a member of Dr. Benamin Ebert’s Laboratory, and a Senior Staff Scientist at the Dana-Farber Cancer Institute. Dr. Słabicki employs functional genomics, high-throughput screening, chemical biology, cell biology, and biochemical techniques to identify and characterize new molecular glue degraders and novel mechanisms of targeted protein degradation. Dr. Słabicki is a founding co-organizer of the Dana-Farber Targeted Protein Degradation Webinar series that features biweekly talks from experts in the field.

 

Dr. Słabicki’s research expanded the repertoire of molecular glue degraders and showed that the CDK inhibitor, CR8, induced degradation of cyclin K without a canonical substrate receptor. His research also identified an alternative mechanism of targeted protein degradation, in which a small molecule, BI-3802, induces the highly specific, reversible polymerization and subsequent degradation of the transcription repressor BCL6.

 

Dr. Słabicki graduated with an M.S. in Biotechnology from the Technical University of Łódź, in Poland and completed his Ph.D. under the guidance of Dr. Frank Buchholz at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Dr. Słabicki completed his post-doctoral research as a Marie Skłodowska Curie Scholar in Dr. Benjamin Ebert’s laboratory at the Dana-Farber Cancer Institute in Boston, United States, and in Stefan Fröhling’s laboratory at the German Cancer Research Center in Heidelberg, Germany.